Article

Southeast Asia Golden Window for Going Global

Published on 03.06

Southeast Asia's "Golden Window" for Going Global: Malaysia's Healthcare Market, the Next Focus for Chinese Pharmaceutical and Medical Device Companies

With the dual advantages of policy dividends and market potential, Malaysia is becoming a bridgehead for Chinese pharmaceutical and medical device companies to expand into ASEAN. As competition in the domestic healthcare market intensifies, expanding overseas has become an essential path for Chinese companies to achieve strategic development. The Southeast Asian market, with its close cultural and geographical ties to China, especially Malaysia, is attracting increasing attention from Chinese pharmaceutical and medical device companies with its unique market advantages and policy benefits. As an important member of ASEAN, Malaysia not only possesses a sound healthcare system and broad market prospects but also provides a convenient channel for rapid market access for Chinese pharmaceutical and medical device companies through a series of bilateral cooperation agreements. This article primarily analyzes the Malaysian healthcare market environment and provides strategic references for Chinese pharmaceutical and medical device companies going global.

1. Overview of Malaysia's Population and Healthcare Market

Malaysia is a diverse country with a population of approximately 34.2 million (2024 data), comprising 70.1% Malays, 22.6% Chinese, and 6.6% Indians. This diverse ethnic composition makes Malaysia a melting pot of cultures and provides a vast market for various types of medical and equipment products. In terms of population age structure, children aged 0-14 account for 25.6% of the total population, the working-age population aged 15-64 is as high as 69.1%, and the elderly aged 65 and above constitute 5.3%. This indicates that Malaysia is in a period of demographic dividend, with a high proportion of the working-age population and strong demand for healthcare. At the same time, Malaysia is also facing a trend of accelerating population aging. It is projected that by 2030, the elderly population aged 65 and above will account for 15.3% of the total population. The direct consequence of aging is the rise in the incidence of chronic diseases, especially cardiovascular diseases and diabetes, leading to a significant increase in medical demand.

Malaysia's healthcare system is composed of both public and private hospitals. According to statistics from 2023, public hospitals and public health service centers dominate nationwide, with a total of 149 and 3,114 facilities, respectively. These hospitals are managed and funded by the government and primarily serve Malaysian citizens, with different fee structures for foreign residents. Additionally, private hospitals and private medical diagnostic institutions are also flourishing, with a total of 212 and over 10,000 facilities, respectively. These hospitals are mainly concentrated in urban areas, offering higher quality medical services but at relatively higher costs. In terms of healthcare expenditure, the Malaysian government continues to increase its investment. In 2023, Malaysia significantly boosted its healthcare budget by 12.6% to $8.6 billion, with a portion of these funds specifically allocated for the upgrade of medical facilities. This initiative has effectively promoted the expansion of the domestic medical equipment market, creating broader space for industry development.

In terms of hospital procurement, these two distinctly different healthcare systems exhibit significant differences in the procurement of medical products. Public hospitals implement a unified government centralized procurement model: relevant government departments or specialized agencies first consolidate the actual clinical needs of various hospitals and formulate specific procurement plans and budgets accordingly; procurement decisions need to comprehensively consider cost control, product quality reliability, and supply stability as three core dimensions. However, due to limitations in funding and resource allocation, public hospitals often face significant challenges in introducing cutting-edge treatment technologies such as stem cell therapy and high-end medical AI products.

Unlike public hospitals, private hospitals have more flexibility and autonomy in their procurement decisions. They plan their procurement direction based on their own business positioning, financial situation, and market dynamics, and are therefore more willing to proactively invest in high-end technologies such as medical AI products and minimally invasive surgical robots, as well as comprehensive solutions that can directly improve diagnostic and treatment efficiency and enhance market competitiveness. It should be noted that in the procurement process of private hospitals, relationship maintenance is a key driving factor. Companies need to patiently navigate through all decision-making stages. Localized operation teams, with their familiarity with local market rules and resource integration capabilities, play an indispensable and important role in this process.

2. Pharmaceutical Market Potential and Demand Characteristics

The Malaysian pharmaceutical market is showing a vigorous trend of rapid expansion, becoming a highly watched emerging market hotspot. According to Statista's forecast, the revenue of the Malaysian pharmaceutical market will reach US$1.74 billion in 2025, with an annual growth rate of 4.87% from 2025 to 2029, and the market size will reach US$2.1 billion in 2029. The potential of the Malaysian pharmaceutical market is mainly reflected in three aspects:

First, the demand for chronic disease treatment continues to grow. With the acceleration of Malaysia's aging population, the incidence of chronic diseases is constantly increasing. Statistics show that chronic diseases (cardiovascular and cerebrovascular diseases, diabetes, etc.) account for 75% of Malaysia's disease burden. Cardiovascular diseases account for 1/3 of the total deaths, which creates a stable and growing demand for related drugs and medical devices.

Second, the foundation of the local pharmaceutical industry is relatively weak. The foundation of Malaysia's local pharmaceutical industry needs to be strengthened, with significant room for improvement in independent research and development capabilities, and a high dependence on imported drugs. The proportion of imported drug expenses in countries such as Malaysia, Vietnam, and the Philippines exceeds 50%, mainly consisting of originator drugs from multinational pharmaceutical companies. This provides huge market opportunities for Chinese pharmaceutical companies.

Third, the similarity in ethnicity and disease spectrum with China. Compared to Europe and the United States, Southeast Asian countries have a higher proportion of Asian populations, with smaller ethnic differences and higher recognition of clinical data for new Chinese drugs. According to IHME (an independent global health research institution affiliated with the University of Washington), seven of the top ten diseases in China and Southeast Asia in 2019 were the same. Drugs developed based on the disease characteristics of the Chinese population should also be applicable to the disease characteristics of the ASEAN population. In addition, Malaysia is vigorously developing its medical tourism industry, attracting a large number of patients from surrounding Southeast Asian regions and even the Middle East with its high-quality medical services and unique tourism resources. This further drives the demand growth in the Malaysian pharmaceutical market.

3. China-Malaysia Pharmaceutical and Medical Device Cooperation Fast Track

In recent years, cooperation in the pharmaceutical field between China and Malaysia has been continuously deepening, opening up multiple "fast tracks" for Chinese pharmaceutical and medical device companies to enter the Malaysian market.

(1) China-ASEAN Pharmaceutical Regional Centralized Procurement Platform

On January 9, 2025, the China-ASEAN Pharmaceutical Regional Centralized Procurement Platform was officially launched, marking China's first cross-border regional centralized procurement platform. The platform includes the China-ASEAN Pharmaceutical Regional Centralized Procurement and Trading Platform and the Medical Insurance Cloud Platform + N Information Platform, providing greater convenience for people in ASEAN countries to seek medical treatment.

The centralized procurement platform provides a "fast track" for Chinese pharmaceutical and medical device companies to enter the ASEAN market. By the end of 2025, the platform plans to focus on Traditional Chinese Medicine and drugs for local special diseases, conducting regional centralized procurement between China and ASEAN countries to further expand the market share of domestic drugs and consumables. This presents a good opportunity for Chinese pharmaceutical and medical device companies to reduce market development costs and quickly enter the Malaysian market.

(2) Medical Device Approval Mutual Recognition Agreement

In November 2023, the National Medical Products Administration of China and the Malaysian Medical Device Authority jointly signed the "Memorandum of Understanding on Cooperation in Medical Devices between the National Medical Products Administration of the People's Republic of China and the Malaysian Medical Device Authority." This agreement ultimately led to an important decision by both sides to mutually recognize each other's pre-market approval and regulation of medical devices. Under this new cooperation mechanism, the approval time for Chinese medical devices to enter the Malaysian market will be shortened to approximately 30 working days, significantly improving product launch efficiency. Even more beneficial is that Chinese medical device companies entering the Malaysian market will not need to conduct clinical trials or undergo repeated testing. As long as the product design, materials, and indications remain unchanged, they can pass customs as is. This policy will officially take effect on July 30, 2025.

(3) Protocol on the Upgrading of the China-ASEAN Free Trade Area Version 3.0

Recently, the protocol for the upgrade of the China-ASEAN Free Trade Area Version 3.0 was signed in Kuala Lumpur, Malaysia, marking the first time that pharmaceuticals are included in the market opening and rule alignment clauses. This signifies that pharmaceutical trade within the region has entered a new stage of institutional opening. The protocol proposes the goal of "mutual recognition of drug registration standards", which means that the "fast track" for the Chinese pharmaceutical industry to enter the Southeast Asian market on a large scale will be opened up, driven by both policy and regional cooperation.

4. Malaysian Market Overview and Forecast (2026-2031)

The Malaysian healthcare market is showing a steady growth trend, with continuous development dividends being released from the policy side. Among them, the medical device industry, relying on government-led modernization reforms and active private capital investment, has become the core leading sector in terms of compound annual growth rate (CAGR).

(1) Pharmaceutical Industry

In Malaysian Ringgit (MYR), the industry market size is expected to reach 15.7 billion Ringgit in 2025, with a stable compound annual growth rate (CAGR) of 6.4% over the past five years; in the long term, the market size is expected to further climb to 21.4 billion Ringgit in 2029, showing significant growth resilience.

(2) Medical Device Industry

Calculated based on historical data from 2023-2024, the current market valuation is approximately 3.2 billion USD. The future growth potential is even more prominent, with a projected compound annual growth rate (CAGR) of 8.5%-9.5% from 2028-2030, significantly outpacing the pharmaceutical industry. This strong growth momentum is primarily driven by two core pillars: first, the strategic focus of Malaysia's "New Industrial Master Plan 2030" (NIMP) on high-value-added medical device manufacturing; and second, the continuous advancement of large-scale hospital modernization projects nationwide, directly boosting the expansion of the medical device market demand.

(3) Pharmaceutical Industry

Supported by stable orders from government procurement and the rigid demand brought about by the aging population, the industry maintains a steady and predictable growth rhythm, serving as a crucial anchor in the healthcare market.

5. Hub Potential: ASEAN and the Organization of Islamic Cooperation

Malaysia, leveraging its established advantages and regulatory compliance as a regional launchpad, leads regional trade and production.

6. Market Entry Strategies for Chinese Pharmaceutical and Medical Device Companies in Malaysia

Considering the characteristics of the Malaysian market, Chinese pharmaceutical and medical device companies can adopt various market entry strategies. Depending on their own strengths and product features, they can choose the most suitable path for international expansion.

(1) Product Export Model

This is the most traditional and direct way to enter overseas markets. Companies export their products directly to the Malaysian market without establishing local production bases or joint ventures. This approach is suitable for initial market exploration or for companies with limited resources. In recent years, many Chinese pharmaceutical and medical device companies have successfully entered the Malaysian market using this model. For example, Sugenoglutide Sodium Injection by Luannan Pharmaceutical, Rivaroxaban Tablets by Shanghai Pharmaceuticals, and Aspart Insulin Injection by Tonghua Dongbao have successively obtained marketing approval in the Philippines, Malaysia, and Indonesia. The key to the success of this model lies in: first, precise planning, targeting high-incidence disease spectra and market demands in different countries for focused penetration; and second, strategic site selection, prioritizing countries with relatively transparent registration processes and more complete regulatory systems, such as Malaysia and Indonesia, to reduce uncertainty risks.

(2) Cooperative Licensing Model

For innovative drug and medical device companies holding significant products, cooperative licensing is a more agile and capital-efficient strategy. Companies license their commercialization rights in specific regions to local partners, leveraging their established sales networks and market experience to quickly open up the market. Fosun Pharma is an excellent example, which successfully entered the markets of five countries including Singapore and Malaysia in 2025 by granting partial commercialization rights of its serplulimab in ten ASEAN countries to KG Bio. This path is particularly suitable for high-value innovative drugs and cutting-edge therapies, but its success also depends on precise strategic planning. It is recommended that companies establish a synchronized layout in multiple countries to form economies of scale, while selectively entering markets through authorized partners with strong capabilities within the region, avoiding countries with weaker payment capabilities.

(3) NewCo Model

The NewCo model is a more sophisticated way to go global. Its core operation is to establish a China-controlled joint venture company in the target market, and conduct localized operations through this offshore entity. For example, after Linkage Group established a controlling joint venture company in Indonesia in 2024, its GLP-1 dual-target drug LM008 became the first product of its kind in Indonesia to enter the clinical green channel. This model is particularly suitable for innovative drugs with sensitive data, and for countries with strong localization policies such as Indonesia, which have mandatory technology transfer and require localized production. 

(4) Heavy Asset Localization Go-Global Model

At the far end of the spectrum of commitment and investment is the heavy asset localization go-global model. This typically means acquiring local production capacity, market channels, and even brand assets through cross-border mergers and acquisitions or direct investment in building factories, achieving the deepest localization. In May of this year, Livzon Pharmaceutical Group's acquisition of a majority stake in Vietnam IMP Pharmaceutical Company was a vivid practice of this strategy. By controlling IMP's established channels and production resources in Vietnam, Livzon was able to accelerate its strategic layout throughout Southeast Asia. This path is particularly suitable for generic drugs with huge market demand (such as antihypertensives and antidiabetics), biological products that rely on cold chain transportation, or products that are easily affected by trade protectionism. In terms of site selection, priority should be given to countries with cost advantages and policy support, such as Vietnam and Indonesia, to maximize benefits.

7. Value and Benefits of Obtaining a Malaysian Registration Certificate

For Chinese pharmaceutical and medical device companies, obtaining a Malaysian drug registration certificate holds multiple strategic values, far exceeding the significance of entering a single market itself.

(1) Rapid Entry into ASEAN Markets

Malaysia is located in the core of Southeast Asia, serving as a crucial gateway to the ASEAN market and a vital link to regions like the Middle East, Australia, and New Zealand. It plays a key role as a "transit hub" in the global supply chain. Products registered in Malaysia can more easily enter other ASEAN markets due to Malaysia's high regulatory recognition within ASEAN. Approved products in Malaysia receive a certain degree of recognition in other ASEAN countries, significantly reducing market access costs for businesses.

(2) Enjoy Policy Dividends

With the full implementation of RCEP (Regional Comprehensive Economic Partnership), new institutional dividends are further strengthening economic and trade ties between China and ASEAN. Products registered in Malaysia can benefit from preferential policies such as tariff reductions, lowering trade costs and enhancing market competitiveness. Furthermore, the China-ASEAN Free Trade Area 3.0 upgrade protocol proposes the goal of "mutual recognition of drug registration standards," which means that products registered in Malaysia may receive expedited approval in the Chinese market in the future, achieving mutual recognition in both directions.

(3) Enhance International Brand Image

Malaysia's pharmaceutical regulatory system is relatively well-established. Obtaining its PIC/S GMP certification signifies that the product's quality, safety, and efficacy have received international recognition, which helps to enhance the company's international brand image. For Chinese pharmaceutical and medical device companies planning to expand into broader international markets, Malaysia can serve as an ideal "testing ground" and "springboard." Through successful operations in the Malaysian market, companies can accumulate international experience, laying the foundation for entering more strictly regulated markets (such as Europe and the United States).

(4) Cost-Effectiveness Advantage

Compared to developed country markets, the cost of product registration and marketing in Malaysia is relatively low, but the return on investment is high. Especially considering Malaysia's high per capita income and strong purchasing power, the return on investment is considerable. According to projections from the "Global Pharmaceutical Spending and Usage Trends Outlook Report 2026," the pharmaceutical market for nearly 700 million people in Southeast Asia is growing annually at 5%~8%, significantly higher than the 2.5%~5.5% growth in developed markets. Coupled with its geographical proximity to China, it has become a key region for Chinese pharmaceutical and medical device companies to focus on for overseas expansion, allowing them to benefit from market growth.

8. Sharing Successful Cases of China-Malaysia Cooperation

In recent years, China and Malaysia have cooperated closely in fields such as investment and financing, traditional medicine, and regulation. Many Chinese enterprises have achieved remarkable success in the Malaysian market, and their experiences are worth learning from. For example, Wisdom Pharmaceutical has signed a strategic cooperation framework agreement with Universiti Malaya and other institutions to cooperate in areas such as drug discovery and development, and will jointly establish a laboratory with Universiti Malaya. CSPC Pharmaceutical Group and Pharmaniaga Berhad have reached a strategic consensus on cooperation in the fields of mRNA vaccines and high-end formulations. Livzon Pharmaceutical Group acquired Singapore WBM Pharmaceutical Commercial Company and is building a marketing network in Malaysia. United Imaging Group has signed a strategic cooperation agreement with KPJ Healthcare Malaysia to carry out cooperation such as technical exchanges and establish production bases in Malaysia.

9. Strategic Recommendations for 2026-2031

Conclusion: As China and Malaysia deepen their cooperation in the medical device sector, both sides are working together to build a closer community of health. The future Malaysian healthcare market will undoubtedly see more Chinese medical device companies, which will not only bring high-quality medical device products to local patients but also serve as an important bridge for China-ASEAN healthcare cooperation. Opportunities favor the prepared. Chinese medical device companies should seize the current policy window period in the Malaysian market, formulate long-term strategies, achieve localized deep cultivation, and build Malaysia into a strategic foothold radiating the entire ASEAN market.

(This article is for medical industry policy interpretation and knowledge sharing only. The content is for reference only. Please indicate the original source if reprinted.)